Curevac AG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Curevac AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013942
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Curevac AG (Curevac), formerly CureVac GmbH is a clinical stage biopharmaceutical company that develops RNA-based medicines. The company designs, develops and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RNA technology platforms include RNAntibody, RNArt, RNActive, and RNAdjuvant. Curevac’s RNActive technology is used to develop treatments against cancer and prophylactic vaccines for infectious diseases. The company’s RNAdjuvant technology is used to enhance the immune response of other vaccines. Its products are used in the treatment of prostate cancer and non-small cell lung cancer; and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. The company program the RNA molecule to address a specific medical need. It operates through pharmaceutical companies and research institutes. CureVac is headquartered in Tubingen, Germany.

Curevac AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Curevac AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
CureVac to Raise USD76 Million in Venture Financing 10
CureVac Raises US$105 Million In Series D Financing 11
Partnerships 12
Eli Lilly and CureVac Enter into Partnership 12
International AIDS Vaccine Partners with CureVac 13
CureVac to Enter into Development Agreement with Bill & Melinda Gates 14
Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 15
CureVac Enters Into Co-Development Agreement With Sanofi Pasteur 16
Licensing Agreements 17
CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20
Equity Offering 21
CureVac Raises Additional USD29.5 Million in Private Placement 21
CureVac Raises USD110 Million in Private Placement of Shares 22
Curevac AG – Key Competitors 23
Curevac AG – Key Employees 24
Curevac AG – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Strategy And Business Planning 26
Oct 30, 2017: CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics 26
Corporate Communications 27
Oct 11, 2016: CureVac Appoints Pierre Kemula as Chief Financial Officer 27
Mar 18, 2016: CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion 28
Government and Public Interest 29
Feb 18, 2016: CureVac announces “MERAN” has been approved by the WHO as suffix for mRNA drug substances 29
Product News 30
Oct 23, 2017: Publication in npj Vaccines Demonstrates CureVac’s RNActive Vaccine is Superior to Licensed Vaccines 30
Clinical Trials 31
Dec 05, 2016: Study with CureVac’s RNAdjuvant Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma Patients and Healthy Subjects to the RNA-based adjuvant 31
Other Significant Developments 32
Jun 26, 2017: CureVac Expands GMP Production Capacities for RNA Products 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Curevac AG, Pharmaceuticals & Healthcare, Key Facts 2
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Curevac AG, Deals By Therapy Area, 2011 to YTD 2017 8
Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CureVac to Raise USD76 Million in Venture Financing 10
CureVac Raises US$105 Million In Series D Financing 11
Eli Lilly and CureVac Enter into Partnership 12
International AIDS Vaccine Partners with CureVac 13
CureVac to Enter into Development Agreement with Bill & Melinda Gates 14
Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 15
CureVac Enters Into Co-Development Agreement With Sanofi Pasteur 16
CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20
CureVac Raises Additional USD29.5 Million in Private Placement 21
CureVac Raises USD110 Million in Private Placement of Shares 22
Curevac AG, Key Competitors 23
Curevac AG, Key Employees 24
Curevac AG, Other Locations 25
Curevac AG, Subsidiaries 25

★海外企業調査レポート[Curevac AG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bonduelle Sca:企業の戦略・SWOT・財務分析
    Bonduelle Sca - Strategy, SWOT and Corporate Finance Report Summary Bonduelle Sca - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Chang Chun Petrochemical Co Ltd:企業の戦略的SWOT分析
    Chang Chun Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Sino Gas & Energy Holdings Ltd (SEH):企業の財務・戦略的SWOT分析
    Summary Sino Gas & Energy Holdings Ltd (Sino Gas), a subsidiary of MIE Holdings Corp, is an oil and gas company that explores and develops unconventional gas assets production sharing contracts. The company holds working interest in the Linxing PSC and the Sanjiaobei PSC projects. It has strategic A …
  • AstraZeneca PLC:企業のM&A・事業提携・投資動向
    AstraZeneca PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AstraZeneca PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • SDIX LLC:医療機器:M&Aディール及び事業提携情報
    Summary SDIX LLC (SDIX), a subsidiary of OriGene Technologies Inc, is an immuno-solutions company that develops antibody-based solutions. The company provides IVD solutions and premade antibiotics, among others. Its IVD solutions provide co-development of analyte-specific reagents, diagnostic menu e …
  • Enterome Bioscience SA-医療機器分野:企業M&A・提携分析
    Summary Enterome Bioscience SA (Enterome) is a drug development company that develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome- …
  • Mari Petroleum Co Ltd (MARI):企業の財務・戦略的SWOT分析
    Mari Petroleum Co Ltd (MARI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Quark Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Quark Pharmaceuticals Inc (Quark), a subsidiary of SBI Biotech Co Ltd, is a clinical-stage pharmaceutical company in the development of novel RNAi-based therapeutics. It offers under development products which include PF-655, a synthetic siRNA which is used for the treatment of diabetic macu …
  • Cheng Shin Rubber Ind. Co Ltd (2105):企業の財務・戦略的SWOT分析
    Cheng Shin Rubber Ind. Co Ltd (2105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Nutra Pharma Corp (NPHC):企業の財務・戦略的SWOT分析
    Nutra Pharma Corp (NPHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • NovoCure Ltd (NVCR)-製薬・医療分野:企業M&A・提携分析
    Summary NovoCure Ltd (NovoCure) is an drug company that concentrates on the development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in various types of cancer indications such as ovarian cancer, malignant melanoma, hepatocellul …
  • Tivo Corporation:戦略・SWOT・企業財務分析
    Tivo Corporation - Strategy, SWOT and Corporate Finance Report Summary Tivo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Albireo Pharma Inc (ALBO):医療機器:M&Aディール及び事業提携情報
    Summary Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe med …
  • Kimball International Inc (KBAL):企業の財務・戦略的SWOT分析
    Kimball International Inc (KBAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Diplomat Pharmacy Inc (DPLO):企業の財務・戦略的SWOT分析
    Diplomat Pharmacy Inc (DPLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Raysearch Laboratories AB (RAY B):医療機器:M&Aディール及び事業提携情報
    Summary RaySearch Laboratories AB (RaySearch) is a medical technology company that develops software solutions for radiation therapy of cancer. The company provides software products such as rayplan, raystation and raycare. Its services include installation, support, training and training schedule. …
  • Arden Partners Plc (ARDN):企業の財務・戦略的SWOT分析
    Summary Arden Partners Plc (Arden) is a multi-service stockbroker that provides a range of financial services to corporate and institutional clients. The company offers research, distribution, execution and corporate finance services. Its distribution services include providing unique trading though …
  • Rio Grande Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Rio Grande Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Lagardere SCA:企業のM&A・事業提携・投資動向
    Lagardere SCA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lagardere SCA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Europlasma SA (ALEUP):企業の財務・戦略的SWOT分析
    Europlasma SA (ALEUP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆